Your Health, We Care

Home > Photo Wall > Honor and qualification

Production approval for Augtyro

Release date: 2024-07-09 15:48:21     Recommended: 89

02L1071_24 瑞普替尼 批文_00.jpg

Augtro is suitable for the treatment of locally advanced or metastatic ROS1 positive non-small cell lung cancer (NSCLC). Riptinib is suitable for treating adult patients with locally advanced or metastatic ROS1 positive non-small cell lung cancer (NSCLC).

Company News

Research News

Drug news